Generic Product News (November 2015)

Publication
Article
Pharmacy TimesNovember 2015 Cough, Cold, & Flu
Volume 81
Issue 11

Read about the new generic products featured in November.

Winthrop (a division of Sanofi)

Compare to: Arava (Sanofi)

Indication: Sanofi has announced the availability of Leflunomide Tablets, a generic equivalent to the company’s Arava rheumatoid arthritis (RA) drug, in 10-mg and 20-mg dosage strengths. The product is indicated to treat moderate to severe RA in adults by inhibiting structural damage, as evidenced by x-ray erosions and joint space narrowing, and to improve physical function.

Dosage Forms: Tablets: 10 mg and 20 mg

For More Information: sanofi.com

Calcium Acetate Capsules 667 mgMarketed by: Heritage Pharmaceuticals

Compare to: PhosLo (Fresenius Medical Care)

Indication: Heritage Pharmaceuticals has announced the availability of Calcium Acetate Capsules, the generic equivalent to PhosLo, in a 667-mg dosage strength. The phosphate-binding drug is indicated to reduce serum phosphorus in adult patients with end-stage renal disease.

Dosage Form: Capsules: 667 mg

For More Information: heritagepharma.com

Gemfibrozil Tablets, USPMarketed by: Aurobindo Pharma USA, Inc

Compare to: Lopid (Pfizer)

Indication: Aurobindo Pharma has received FDA approval for Gemfibrozil Tablets, USP, the therapeutic equivalent of Pfizer’s Lopid Tablets, in a 600-mg dosage strength. The product is indicated as an adjunctive therapy to diet for the treatment of adult patients with high elevations of serum triglyceride levels (types IV and V hyperlipidemia). The product also reduces the risk of developing coronary heart disease in type IIb patients only.

Dosage Form: Tablets: 600 mg

For More Information: aurobindo.com

Clopidogrel Tablets, USPMarketed by: Camber Pharmaceuticals

Compare to: Plavix (sanofi-aventis)

Indication: Camber Pharmaceuticals announced the launch of Clopidogrel Tablets, the therapeutic equivalent to sanofi-aventis’s Plavix, in 75-mg dosage strengths in 30-, 90-, and 500- count bottles. The product is indicated for patients with non-ST-segment elevation acute coronary syndrome or patients with a history of recent myocardial infarction, recent stroke, or established peripheral arterial disease.

Dosage Form: Tablets: 75 mg

For More Information: camberpharma.com

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.